Warburg-Mubadala leads race to buy majority in Soframycin maker

Exciting developments are afoot as Encube Ethicals, a key player in the pharma contract manufacturing sector, approaches a significant acquisition. The frontrunners, Warburg Pincus and Mubadala, are intensifying their bids, valuing the company at approximately ₹16,500 crore. This move underscores the burgeoning interest investors have in Indian CDMO companies, fueled by global supply chain shifts and evolving US policies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x2Wz09B
via IFTTT

Read More

French pharma giant Servier to invest €15 million to launch global single-pill platform 'GATINN' in India

French pharma group Servier is expanding in India with a €15 million investment to launch GATINN, a global platform for single pill combinations (SPCs) targeting cardiometabolic and venous diseases. The India-based hub will coordinate research, manufacturing, and exports to international markets, aiming to improve patient adherence by combining multiple drugs into a single daily dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ePsq5ZK
via IFTTT

Read More

IHH Healthcare, Fortis launch initiative to strengthen healthcare innovation ecosystem

IHH Healthcare, in partnership with Fortis Healthcare, is proud to introduce IHH Catalyst. This groundbreaking initiative is designed to fast-track the integration of innovative technology in healthcare across India. By empowering promising health-tech and med-tech startups to shift from concept to concrete implementation, IHH Catalyst aims to elevate patient care and optimize hospital processes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KRwBh2b
via IFTTT

Read More

AstraZeneca gets CDSCO nod to market cancer drug Imfinzi for additional indication

AstraZeneca Pharma India has secured approval from India's drug regulator for Durvalumab, marketed as Imfinzi. This new indication allows its use in treating advanced or recurrent endometrial cancer. The drug will be administered in combination with other therapies for initial treatment. Following this, Durvalumab will be used as maintenance therapy for specific patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kXT7w6P
via IFTTT

Read More

Lupin clears Mirabegron patent dispute with Astellas in $90 million deal, secures US sales continuity

Drugmaker Lupin has settled a patent infringement dispute with Astellas Pharma over its Mirabegron product for $90 million. The agreement includes a $75 million prepaid option payment and a per-unit license fee. This resolution allows Lupin to continue marketing Mirabegron in the U.S., removing a significant legal obstacle.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TxGzH5g
via IFTTT

Read More

Decide on Piramal's Dahej plant in a week: Supreme Court to Gujarat Pollution Control Board

The Supreme Court has issued a swift order for the Gujarat Pollution Control Board to review Piramal Pharma's appeal to reactivate its Dahej manufacturing site, which was closed due to serious allegations related to hazardous waste management. The firm sought interim relief but was turned down by the court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uUl4syC
via IFTTT

Read More

Sampre Nutrition arm to set up facility in Egypt

Sampre Nutrition will expand its global reach with a new manufacturing unit in Egypt. Orascom Industrial Parks has approved land for food processing and confectionery. This facility will boost production and support international growth. The company recently partnered with Reliance Consumer Products. Sampre Nutrition saw a significant revenue increase in the first half of the year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kn7VzqW
via IFTTT

Read More